CompletedPhase 3NCT04830813

Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer

Studying Cap myopathy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chipscreen Biosciences, Ltd.
Principal Investigator
Yuankai Shi
Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
Intervention
Chiauranib(drug)
Enrollment
184 enrolled
Eligibility
18-75 years · All sexes
Timeline
2021 – 2024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04830813 on ClinicalTrials.gov

Other trials for Cap myopathy

Additional recruiting or active studies for the same condition.

See all trials for Cap myopathy →

← Back to all trials